PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Left ventricular dysfunction

Drugs in development · updated 30 October 2026

Left ventricular dysfunction: drugs in development

As of 30 October 2026 there are 9 active clinical trials (recruiting or ongoing, phases I–III) on 10 drugs for left ventricular dysfunction. 0 are experimental, that is not yet approved in the United States.

9Active trials
0Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
FinerenoneBAY94-8862, KerendiaIII2NCT07192952
ApixabanEliquis, Abanta®III1NCT06742567
DapagliflozinForxiga, Dapagliflozin PropanediolIII1NCT05764057
LosartanArbli®, Cozaar®III1NCT05619653
MethylprednisoloneMethylprednisolon, MethylprenisoloneIII1NCT06522100
MidodrineProamatine®II–III1NCT06405555
PrednisolonePrednisolon, PrenisoloneIII1NCT05619653
PrednisonePredinisone, CortancylIII1NCT06522100
VericiguatVerquvo®II–III1NCT05714085
SotagliflozinInpefa®, Zynquista®II1NCT07572175

Sorted by most advanced phase and number of active trials.

All 10 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D018487 “Ventricular Dysfunction, Left”.

ItalianoFrançaisDeutsch